Cargando…
Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
BACKGROUND: The mucosa serves as the first defence against pathogens and facilitates the surveillance and elimination of symbiotic bacteria by mucosal immunity. Recently, the mRNA vaccine against SARS-CoV-2 has been demonstrated to induce secretory antibodies in the oral and nasal cavities in additi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339591/ https://www.ncbi.nlm.nih.gov/pubmed/37443091 http://dx.doi.org/10.1186/s12985-023-02113-z |
_version_ | 1785071879820673024 |
---|---|
author | Ishizaka, Aya Koga, Michiko Mizutani, Taketoshi Uraki, Ryuta Yamayoshi, Seiya Iwatsuki-Horimoto, Kiyoko Yamamoto, Shinya Imai, Masaki Tsutsumi, Takeya Suzuki, Yutaka Kawaoka, Yoshihiro Yotsuyanagi, Hiroshi |
author_facet | Ishizaka, Aya Koga, Michiko Mizutani, Taketoshi Uraki, Ryuta Yamayoshi, Seiya Iwatsuki-Horimoto, Kiyoko Yamamoto, Shinya Imai, Masaki Tsutsumi, Takeya Suzuki, Yutaka Kawaoka, Yoshihiro Yotsuyanagi, Hiroshi |
author_sort | Ishizaka, Aya |
collection | PubMed |
description | BACKGROUND: The mucosa serves as the first defence against pathogens and facilitates the surveillance and elimination of symbiotic bacteria by mucosal immunity. Recently, the mRNA vaccine against SARS-CoV-2 has been demonstrated to induce secretory antibodies in the oral and nasal cavities in addition to a systemic immune response. However, the mechanism of induced immune stimulation effect on mucosal immunity and commensal bacteria profile remains unclear. METHODS: Here, we longitudinally analysed the changing nasal microbiota and both systemic and nasal immune response upon SARS-CoV-2 mRNA vaccination, and evaluated how mRNA vaccination influenced nasal microbiota in 18 healthy participants who had received the third BNT162b. RESULTS: The nasal S-RBD IgG level correlated significantly with plasma IgG levels until 1 month and the levels were sustained for 3 months post-vaccination. In contrast, nasal S-RBD IgA induction peaked at 1 month, albeit slightly, and correlated only with plasma IgA, but the induction level decreased markedly at 3 months post-vaccination. 16 S rRNA sequencing of the nasal microbiota post-vaccination revealed not an overall change, but a decrease in certain opportunistic bacteria, mainly Fusobacterium. The decrease in these bacteria was more pronounced in those who exhibited nasal S-RBD IgA induction, and those with higher S-RBD IgA induction had lower relative amounts of potentially pathogenic bacteria such as Pseudomonas pre-vaccination. In addition, plasma and mucosal S-RBD IgG levels correlated with decreased commensal pathogens such as Finegoldia. CONCLUSIONS: These findings suggest that the third dose of SARS-CoV-2 mRNA vaccination induced S-RBD antibodies in the nasal mucosa and may have stimulated mucosal immunity against opportunistic bacterial pathogens. This effect, albeit probably secondary, may be considered one of the benefits of mRNA vaccination. Furthermore, our data suggest that a cooperative function of mucosal and systemic immunity in the reduction of bacteria and provides a better understanding of the symbiotic relationship between the host and bacteria in the nasal mucosa. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-023-02113-z. |
format | Online Article Text |
id | pubmed-10339591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103395912023-07-14 Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination Ishizaka, Aya Koga, Michiko Mizutani, Taketoshi Uraki, Ryuta Yamayoshi, Seiya Iwatsuki-Horimoto, Kiyoko Yamamoto, Shinya Imai, Masaki Tsutsumi, Takeya Suzuki, Yutaka Kawaoka, Yoshihiro Yotsuyanagi, Hiroshi Virol J Research BACKGROUND: The mucosa serves as the first defence against pathogens and facilitates the surveillance and elimination of symbiotic bacteria by mucosal immunity. Recently, the mRNA vaccine against SARS-CoV-2 has been demonstrated to induce secretory antibodies in the oral and nasal cavities in addition to a systemic immune response. However, the mechanism of induced immune stimulation effect on mucosal immunity and commensal bacteria profile remains unclear. METHODS: Here, we longitudinally analysed the changing nasal microbiota and both systemic and nasal immune response upon SARS-CoV-2 mRNA vaccination, and evaluated how mRNA vaccination influenced nasal microbiota in 18 healthy participants who had received the third BNT162b. RESULTS: The nasal S-RBD IgG level correlated significantly with plasma IgG levels until 1 month and the levels were sustained for 3 months post-vaccination. In contrast, nasal S-RBD IgA induction peaked at 1 month, albeit slightly, and correlated only with plasma IgA, but the induction level decreased markedly at 3 months post-vaccination. 16 S rRNA sequencing of the nasal microbiota post-vaccination revealed not an overall change, but a decrease in certain opportunistic bacteria, mainly Fusobacterium. The decrease in these bacteria was more pronounced in those who exhibited nasal S-RBD IgA induction, and those with higher S-RBD IgA induction had lower relative amounts of potentially pathogenic bacteria such as Pseudomonas pre-vaccination. In addition, plasma and mucosal S-RBD IgG levels correlated with decreased commensal pathogens such as Finegoldia. CONCLUSIONS: These findings suggest that the third dose of SARS-CoV-2 mRNA vaccination induced S-RBD antibodies in the nasal mucosa and may have stimulated mucosal immunity against opportunistic bacterial pathogens. This effect, albeit probably secondary, may be considered one of the benefits of mRNA vaccination. Furthermore, our data suggest that a cooperative function of mucosal and systemic immunity in the reduction of bacteria and provides a better understanding of the symbiotic relationship between the host and bacteria in the nasal mucosa. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-023-02113-z. BioMed Central 2023-07-13 /pmc/articles/PMC10339591/ /pubmed/37443091 http://dx.doi.org/10.1186/s12985-023-02113-z Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Ishizaka, Aya Koga, Michiko Mizutani, Taketoshi Uraki, Ryuta Yamayoshi, Seiya Iwatsuki-Horimoto, Kiyoko Yamamoto, Shinya Imai, Masaki Tsutsumi, Takeya Suzuki, Yutaka Kawaoka, Yoshihiro Yotsuyanagi, Hiroshi Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination |
title | Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination |
title_full | Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination |
title_fullStr | Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination |
title_full_unstemmed | Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination |
title_short | Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination |
title_sort | antibody induction and immune response in nasal cavity by third dose of sars-cov-2 mrna vaccination |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339591/ https://www.ncbi.nlm.nih.gov/pubmed/37443091 http://dx.doi.org/10.1186/s12985-023-02113-z |
work_keys_str_mv | AT ishizakaaya antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination AT kogamichiko antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination AT mizutanitaketoshi antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination AT urakiryuta antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination AT yamayoshiseiya antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination AT iwatsukihorimotokiyoko antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination AT yamamotoshinya antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination AT imaimasaki antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination AT tsutsumitakeya antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination AT suzukiyutaka antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination AT kawaokayoshihiro antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination AT yotsuyanagihiroshi antibodyinductionandimmuneresponseinnasalcavitybythirddoseofsarscov2mrnavaccination |